Details of the Drug Combination

General Information of Drug Combination (ID: DCR7YFJ)

Drug Combination Name
CHLOROXINE Vinpocetine
Indication
Disease Entry Status REF
Diffuse intrinsic pontine glioma Investigative [1]
Component Drugs CHLOROXINE   DMFZBMQ Vinpocetine   DMVN2E6
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: SU-DIPG-XIII
Zero Interaction Potency (ZIP) Score: 22.081
Bliss Independence Score: 28.289
Loewe Additivity Score: 0.183
LHighest Single Agent (HSA) Score: 2.665

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of CHLOROXINE
Disease Entry ICD 11 Status REF
Erythema ME64.0 Approved [2]
Pityriasis simplex N.A. Approved [3]
CHLOROXINE Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Opioid receptor kappa (OPRK1) TTQW87Y OPRK_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
CHLOROXINE Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Early growth response protein 1 (EGR1) OTCP6XGZ EGR1_HUMAN Increases ADR [6]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases ADR [6]
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Increases ADR [6]
------------------------------------------------------------------------------------
Indication(s) of Vinpocetine
Disease Entry ICD 11 Status REF
Ischemic stroke 8B11.5Z Approved [4]
Vinpocetine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Phosphodiesterase 1 (PDE1) TTHQENC NOUNIPROTAC Inhibitor [7]
------------------------------------------------------------------------------------
Vinpocetine Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
------------------------------------------------------------------------------------
Vinpocetine Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [9]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Chloroxine FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5285).
5 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
6 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
7 Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue. Urology. 2009 Jun;73(6):1397-401.
8 Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
9 Effects of phosphodiesterase (PDE) inhibitors on human ether-a-go-go related gene (hERG) channel activity. J Appl Toxicol. 2007 Jan-Feb;27(1):78-85. doi: 10.1002/jat.1201.